In some clinical cancer patients, PD-1 is co-expressed in tumor-infiltrating CD8+T cells, and the combined blockade of TIGIT and the barrier in the PD-1/PD-L1 interactions can greatly enhance cytotoxic effect of CD8+T cells [46]. The gene discussed is CD8A; the disease is cancer.